A Pilot Open Labeled Study of Tacrolimus in Alzheimer's Disease.

Alzheimer Disease Clinical Trial

Official title:

A Pilot Open Labeled Study of Tacrolimus to Assess it's Effects on Bio-markers of Mild Cognitive Impairment and Alzheimer's Disease

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT04263519
• Other study ID #: 2019P003904
• Status: Withdrawn
• Phase: Phase 2
• Start date: December 1, 2021
• Est. completion date: January 1, 2023

Study information

• Verified date: September 2021
• Source: Massachusetts General Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

A Pilot open labeled study of Tacrolimus in Alzheimer's Disease.

Description:

This study will investigate the neurobiological effect of tacrolimus in persons with MCI and dementia due to AD by measuring biomarkers of target engagement in immune response, amyloid-b, tau and neurodegeneration in CSF, functional connectivity with MRI and EEG, and cognition. Study objectives include:

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: January 1, 2023
• Est. primary completion date: December 1, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 55 Years to 85 Years

Eligibility

Inclusion Criteria:

Study subjects meeting all of the following criteria will be allowed to enroll in the

study:

1. Age 55-85 inclusive, male or female.

2. Diagnosis of MCI or dementia due to AD as shown by positive AD biomarker (CSF or neuroimaging).

3. Education level, English language skills and literacy indicates subject will be able to complete all assessments.

4. Willing and able to complete all assessment and study procedures, including phlebotomies, lumbar punctures, MRIs, neurocognitive testing.

5. Subject has a study partner with at least two days of contact per week and willingness to assist with subject's research activities.

6. If on cholinesterase inhibitor and/or memantine, doses are stable for 3 months prior to baseline. Exclusion Criteria: Subjects meeting any of the following criteria during the screening evaluation will be

excluded:

1. Allergy or hypersensitivity to tacrolimus.

2. Any specific CNS disease other than suspected AD, such as major clinical stroke, brain tumor, normal pressure hydrocephalus, multiple sclerosis, significant head trauma with persistent neurological of cognitive deficits or complaints, Parkinson's disease, frontotemporal dementia, and/or other neurodegenerative diseases.

3. Any significant systemic illness or clinically significant unstable medical condition that could affect subject safety or compliance with the study; including but not limited to any active infection, active malignancy except non-melanomatous skin cancers, cirrhosis, active hepatitis, uncontrolled diabetes (A1c >8), AIDS, common variable immunodeficiency, conditions treated with biologics, uncontrolled hypertension, chronic kidney disease with an eGFR <45 ml/min, Platelets < 100K, Hgb <9.

4. History of alcohol or other substance abuse or dependence with the past two years.

5. Major active psychiatric illness (e.g. depression, bipolar disorder, obsessive compulsive disorder, schizophrenia) within the previous year.

6. Current suicidal ideation or history of suicide attempt.

7. Contraindications to undergo MRI studies:

1. History of a cardiac pacemaker or pacemaker wires,

2. Metallic particles in the body,

3. Vascular clips in the head,

4. Prosthetic heart valves, or

5. Severe claustrophobia impeding ability to participate in an imaging study.

8. MRI findings that show one or more of the following:

1. More than 4 incidental microhemorrhages,

2. Incidental lacunar infarcts with attributable signs or symptoms and with history of stroke,

3. Incidental meningiomas with attributable signs or symptoms, or

4. Newly recognized meningioma.

9. Laboratory abnormalities in B12, TSH, or other common laboratory parameters that may contribute to cognitive dysfunction.

10. Laboratory abnormalities in PT-INR, CBC, electrolytes, magnesium, LFTs, BUN, Cr or others, or abnormalities in ECG posing risk to treatment with tacrolimus.

11. Current use of medications with psychoactive properties (e.g., anticholinergics, antihistamines, antipsychotics, sedative hypnotics, anxiolytics) that may deleteriously affect cognition in the judgement of the investigator.

12. Current use of medications that interact with tacrolimus (protease inhibitors, macrolides, rifampin, barbiturates, phenytoin, or azoles).

13. Inability to avoid any dietary supplements that could interact with tacrolimus metabolism.

14. Inability to avoid grapefruit and grapefruit juice.

15. Use of other small molecule or device-based investigational agents one month prior to entry and for the duration of the trial; or participation in any immunotherapy clinical trial within three months prior to baseline visit.

16. Discontinuation of cholinesterase inhibitor or memantine within one month (28 days) prior to baseline visit.

17. Females who are pregnant, lactating or of child-bearing potential -

Related Conditions & MeSH terms

• Alzheimer Disease
• Cognitive Dysfunction
• Mild Cognitive Impairment

Intervention

Drug:
• Tacrolimus
Oral Immunosuppressant

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Massachusetts General Hospital

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	CSF biomarkers of target engagement, AD pathology, and neurodegeneration	Evaluate effect of tacrolimus on molecular markers of target engagement (calcineurin/NFAT mediated inflammatory markers IL-2, IL-6, IFNß and YKL-40), AD pathology (amyloid-ß, tau, phospho-tau) and neurodegeneration (neurofilament-light, neurogranin). We will measure change from baseline in all CSF biomarkers following 12 weeks of steady treatment.	Baseline and 12 weeks
Secondary	Blood biomarkers of target engagement, AD pathology, and neurodegeneration.	Evaluate effect of tacrolimus on molecular markers of target engagement (calcineurin/NFAT mediated inflammatory markers IL-2, IL-6, IFNß and YKL-40), AD pathology (amyloid-ß, tau, phospho-tau) and neurodegeneration (neurofilament-light, neurogranin). We will measure change from baseline in all blood biomarkers following 12 weeks of steady treatment.	Baseline and 12 weeks
Secondary	Structural neuroimaging of Hippocampal volume.	Evaluate effect of tacrolimus on size of different brain regions using Magnetic Resonance Imaging (MRI). We will measure change from baseline after 12 weeks of treatment.	Baseline and 12 weeks
Secondary	Functional neuroimaging of default mode network connectivity.	Evaluate effect of tacrolimus on blood flow to different brain regions using functional MRI (fMRI). We will measure change from baseline after 12 weeks of treatment.	Baseline and 12 weeks
Secondary	Electroencephalograms (EEG) spectral power	Evaluate effect of tacrolimus on resting state EEG frequency using the linear power spectral density technique. We will measure change from baseline after 12 weeks of treatment.	Baseline and 12 weeks
Secondary	Montreal Cognitive Assessment (MoCA)	Evaluate effect of tacrolimus on major domains of cognition (score range 0-30, high is better). We will measure change from baseline after 12 weeks of treatment.	Baseline and 12 weeks
Secondary	Neuropsychiatric Inventory Questionnaire (NPIQ)	Evaluate effect of tacrolimus on neuropsychiatric symptoms as rated by a study partner/informant (score range 0-80, high is worse). We will measure change from baseline after 4, 8, and 12 weeks of treatment.	Baseline, 4 weeks, 8 weeks and 12 weeks
Secondary	Functional Activities Questionnaire (FAQ)	Evaluate effect of tacrolimus on ability to daily functional ability as reported by study partner/informant (score range (0-30, low is better). We will measure change from baseline after 4, 8, and 12 weeks of treatment.	Baseline, 4 weeks, 8 weeks and 12 weeks
Secondary	Repeated Battery for the Assessment of Neuropsychological Status	Evaluate the effect of tacrolimus on several domains of cognitive function (score range 40-160, higher is better). We will measure change from baseline after 4, 8, and 12 weeks of treatment.	Baseline, 4 weeks, 8 weeks and 12 weeks